menu
    • menu
    [{"orgOrder":0,"company":"Aditxt","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Preclinical","graph3":"Aditxt","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aditxt \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Formation Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Undisclosed","graph2":"Preclinical","graph3":"Formation Bio","amount2":0.63,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"","amount2New":0.63,"dosageForm":"Undisclosed","sponsorNew":"Formation Bio \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Formation Bio \/ Sanofi"},{"orgOrder":0,"company":"Neoregen Biotech","sponsor":"Circio","pharmaFlowCategory":"D","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Preclinical","graph3":"Neoregen Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neoregen Biotech \/ Circio","highestDevelopmentStatusID":"4","companyTruncated":"Neoregen Biotech \/ Circio"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neoregen Biotech

                            South Korea arrow
                            BIOHK2025
                            Not Confirmed

                            Neoregen Biotech

                            South Korea arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Preclinical

                            Sponsor : Circio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Circio, NeoRegen Biotech to Advance Circular RNA Delivery Collaboration

                            Details : The collaboration between Circio Holding ASA and NeoRegen Biotech is focused on advancing circular RNA (circRNA) expression-based therapeutics toward clinical readiness.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 30, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Preclinical

                            Sponsor : Circio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Formation Bio

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Formation Bio

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gusacitinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $627.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor

                            Details : Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study.

                            Product Name : ASN-002

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 23, 2025

                            Lead Product(s) : Gusacitinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $627.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aditxt

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Aditxt

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aditxt Announces Pricing of $20.0 Million Public Offering

                            Details : The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 16, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth